Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 327

1.

Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers.

Sun B, Mason S, Wilson RC, Hazard SE, Wang Y, Fang R, Wang Q, Yeh ES, Yang M, Roberts TM, Zhao JJ, Wang Q.

Oncogene. 2019 Aug 28. doi: 10.1038/s41388-019-0953-9. [Epub ahead of print]

PMID:
31462705
2.

Molecular Profiling Establishes Genetic Features Predictive of the Efficacy of the p110β Inhibitor KIN-193.

Sethi I, Cai Z, Roberts TM, Yuan GC.

Cancer Res. 2019 Sep 1;79(17):4524-4531. doi: 10.1158/0008-5472.CAN-19-0588. Epub 2019 Jul 10.

PMID:
31292159
3.

PI3 kinase alpha and delta promote hematopoietic stem cell activation.

Hemmati S, Sinclair T, Tong M, Bartholdy B, Okabe RO, Ames K, Ostrodka L, Haque T, Kaur I, Mills TS, Agarwal A, Pietras EM, Zhao JJ, Roberts TM, Gritsman K.

JCI Insight. 2019 May 23;5. pii: 125832. doi: 10.1172/jci.insight.125832.

4.

Canagliflozin in Type 1 Diabetes: A Case Series of Patient Outcomes in a Diabetes Clinic.

Roberts TM, Johnson JF, Vaughan AG.

Diabetes Spectr. 2019 Feb;32(1):47-51. doi: 10.2337/ds17-0018. No abstract available.

PMID:
30853764
5.

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.

Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL.

J Clin Oncol. 2019 Mar 20;37(9):741-750. doi: 10.1200/JCO.18.01207. Epub 2019 Feb 4.

6.

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.

Ding L, Kim HJ, Wang Q, Kearns M, Jiang T, Ohlson CE, Li BB, Xie S, Liu JF, Stover EH, Howitt BE, Bronson RT, Lazo S, Roberts TM, Freeman GJ, Konstantinopoulos PA, Matulonis UA, Zhao JJ.

Cell Rep. 2018 Dec 11;25(11):2972-2980.e5. doi: 10.1016/j.celrep.2018.11.054.

7.

A Conditional Dependency on MELK for the Proliferation of Triple-Negative Breast Cancer Cells.

Wang Y, Li BB, Li J, Roberts TM, Zhao JJ.

iScience. 2018 Nov 30;9:149-160. doi: 10.1016/j.isci.2018.10.015. Epub 2018 Oct 18.

8.

Targeted Profiling of RNA Translation.

Li BB, Qian C, Roberts TM, Zhao JJ.

Curr Protoc Mol Biol. 2019 Jan;125(1):e71. doi: 10.1002/cpmb.71. Epub 2018 Oct 22.

PMID:
30346115
9.

Targeted profiling of RNA translation reveals mTOR-4EBP1/2-independent translation regulation of mRNAs encoding ribosomal proteins.

Li BB, Qian C, Gameiro PA, Liu CC, Jiang T, Roberts TM, Struhl K, Zhao JJ.

Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):E9325-E9332. doi: 10.1073/pnas.1805782115. Epub 2018 Sep 17.

10.

Corrigendum: Identification and Characterisation of a pH-stable GFP.

Roberts TM, Rudolf F, Meyer A, Pellaux R, Whitehead E, Panke S, Held M.

Sci Rep. 2018 May 17;8:46976. doi: 10.1038/srep46976.

11.

Isoform-Selective Phosphatidylinositol 3-Kinase Inhibition in Cancer.

Bergholz JS, Roberts TM, Zhao JJ.

J Clin Oncol. 2018 May 1;36(13):1339-1342. doi: 10.1200/JCO.2017.77.0891. Epub 2018 Mar 8. No abstract available.

PMID:
29517943
12.

Sequence-based prediction of permissive stretches for internal protein tagging and knockdown.

Oesterle S, Roberts TM, Widmer LA, Mustafa H, Panke S, Billerbeck S.

BMC Biol. 2017 Oct 30;15(1):100. doi: 10.1186/s12915-017-0440-0.

13.

Efficient engineering of chromosomal ribosome binding site libraries in mismatch repair proficient Escherichia coli.

Oesterle S, Gerngross D, Schmitt S, Roberts TM, Panke S.

Sci Rep. 2017 Sep 26;7(1):12327. doi: 10.1038/s41598-017-12395-3.

14.

PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.

Bian X, Gao J, Luo F, Rui C, Zheng T, Wang D, Wang Y, Roberts TM, Liu P, Zhao JJ, Cheng H.

Oncogene. 2018 Jan 18;37(3):341-351. doi: 10.1038/onc.2017.326. Epub 2017 Sep 25.

15.

CDK4/6 inhibition triggers anti-tumour immunity.

Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, Khan N, Ubellacker JM, Xie S, Metzger-Filho O, Hoog J, Ellis MJ, Ma CX, Ramm S, Krop IE, Winer EP, Roberts TM, Kim HJ, McAllister SS, Zhao JJ.

Nature. 2017 Aug 24;548(7668):471-475. doi: 10.1038/nature23465. Epub 2017 Aug 16.

16.

A small spacecraft for multipoint measurement of ionospheric plasma.

Roberts TM, Lynch KA, Clayton RE, Weiss J, Hampton DL.

Rev Sci Instrum. 2017 Jul;88(7):073507. doi: 10.1063/1.4992022.

PMID:
28764511
17.

CRKL Mediates p110β-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells.

Zhang J, Gao X, Schmit F, Adelmant G, Eck MJ, Marto JA, Zhao JJ, Roberts TM.

Cell Rep. 2017 Jul 18;20(3):549-557. doi: 10.1016/j.celrep.2017.06.054.

18.

PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α.

Thorpe LM, Spangle JM, Ohlson CE, Cheng H, Roberts TM, Cantley LC, Zhao JJ.

Proc Natl Acad Sci U S A. 2017 Jul 3;114(27):7095-7100. doi: 10.1073/pnas.1704706114. Epub 2017 Jun 19.

19.

The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival.

Wang H, Nicolay BN, Chick JM, Gao X, Geng Y, Ren H, Gao H, Yang G, Williams JA, Suski JM, Keibler MA, Sicinska E, Gerdemann U, Haining WN, Roberts TM, Polyak K, Gygi SP, Dyson NJ, Sicinski P.

Nature. 2017 Jun 15;546(7658):426-430. doi: 10.1038/nature22797. Epub 2017 Jun 7.

20.

Epigenetic regulation of RTK signaling.

Spangle JM, Roberts TM.

J Mol Med (Berl). 2017 Aug;95(8):791-798. doi: 10.1007/s00109-017-1546-0. Epub 2017 Jun 6. Review.

21.

The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer.

Spangle JM, Roberts TM, Zhao JJ.

Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):123-131. doi: 10.1016/j.bbcan.2017.03.002. Epub 2017 Mar 14. Review.

22.

Synthetic Biology for Cell-Free Biosynthesis: Fundamentals of Designing Novel In Vitro Multi-Enzyme Reaction Networks.

Morgado G, Gerngross D, Roberts TM, Panke S.

Adv Biochem Eng Biotechnol. 2018;162:117-146. doi: 10.1007/10_2016_13. Review.

PMID:
27757475
23.

Rac1-mediated membrane raft localization of PI3K/p110β is required for its activation by GPCRs or PTEN loss.

Cizmecioglu O, Ni J, Xie S, Zhao JJ, Roberts TM.

Elife. 2016 Oct 4;5. pii: e17635. doi: 10.7554/eLife.17635.

24.

NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K-AKT and JAK-STAT3 pathways.

Yuzugullu H, Von T, Thorpe LM, Walker SR, Roberts TM, Frank DA, Zhao JJ.

Cell Discov. 2016 Sep 20;2:16030. doi: 10.1038/celldisc.2016.30. eCollection 2016.

25.

Exploiting racemases.

Femmer C, Bechtold M, Roberts TM, Panke S.

Appl Microbiol Biotechnol. 2016 Sep;100(17):7423-36. doi: 10.1007/s00253-016-7729-8. Epub 2016 Jul 22. Review.

PMID:
27444433
26.

Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.

Wang D, Li C, Zhang Y, Wang M, Jiang N, Xiang L, Li T, Roberts TM, Zhao JJ, Cheng H, Liu P.

Gynecol Oncol. 2016 Sep;142(3):548-56. doi: 10.1016/j.ygyno.2016.07.092. Epub 2016 Jul 15.

27.

Tyrosine receptor kinase B is a drug target in astrocytomas.

Ni J, Xie S, Ramkissoon SH, Luu V, Sun Y, Bandopadhayay P, Beroukhim R, Roberts TM, Stiles CD, Segal RA, Ligon KL, Hahn WC, Zhao JJ.

Neuro Oncol. 2017 Jan;19(1):22-30. doi: 10.1093/neuonc/now139. Epub 2016 Jul 10.

28.

Identification and Characterisation of a pH-stable GFP.

Roberts TM, Rudolf F, Meyer A, Pellaux R, Whitehead E, Panke S, Held M.

Sci Rep. 2016 Jun 21;6:28166. doi: 10.1038/srep28166. Erratum in: Sci Rep. 2018 May 17;8:46976.

29.

PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer.

Spangle JM, Dreijerink KM, Groner AC, Cheng H, Ohlson CE, Reyes J, Lin CY, Bradner J, Zhao JJ, Roberts TM, Brown M.

Cell Rep. 2016 Jun 21;15(12):2692-704. doi: 10.1016/j.celrep.2016.05.046. Epub 2016 Jun 9.

30.

Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases.

Ni J, Ramkissoon SH, Xie S, Goel S, Stover DG, Guo H, Luu V, Marco E, Ramkissoon LA, Kang YJ, Hayashi M, Nguyen QD, Ligon AH, Du R, Claus EB, Alexander BM, Yuan GC, Wang ZC, Iglehart JD, Krop IE, Roberts TM, Winer EP, Lin NU, Ligon KL, Zhao JJ.

Nat Med. 2016 Jul;22(7):723-6. doi: 10.1038/nm.4120. Epub 2016 Jun 6.

31.

Delivery strategies and potential targets for siRNA in major cancer types.

Lee SJ, Kim MJ, Kwon IC, Roberts TM.

Adv Drug Deliv Rev. 2016 Sep 1;104:2-15. doi: 10.1016/j.addr.2016.05.010. Epub 2016 May 31. Review.

32.

Transformation by Polyomavirus Middle T Antigen Involves a Unique Bimodal Interaction with the Hippo Effector YAP.

Rouleau C, Pores Fernando AT, Hwang JH, Faure N, Jiang T, White EA, Roberts TM, Schaffhausen BS.

J Virol. 2016 Jul 27;90(16):7032-7045. doi: 10.1128/JVI.00417-16. Print 2016 Aug 15.

33.

Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.

Wang D, Wang M, Jiang N, Zhang Y, Bian X, Wang X, Roberts TM, Zhao JJ, Liu P, Cheng H.

Oncotarget. 2016 Mar 15;7(11):13153-66. doi: 10.18632/oncotarget.7549.

34.

Corrigendum: Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis.

Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ.

Nature. 2016 May 12;533(7602):278. doi: 10.1038/nature16543. Epub 2016 Jan 27. No abstract available.

PMID:
26814969
35.

PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.

Cheng H, Liu P, Ohlson C, Xu E, Symonds L, Isabella A, Muller WJ, Lin NU, Krop IE, Roberts TM, Winer EP, Arteaga CL, Zhao JJ.

Oncogene. 2016 Jun 9;35(23):2961-70. doi: 10.1038/onc.2015.377. Epub 2015 Dec 7.

36.

PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.

Wang Q, Liu P, Spangle JM, Von T, Roberts TM, Lin NU, Krop IE, Winer EP, Zhao JJ.

Oncogene. 2016 Jul 7;35(27):3607-12. doi: 10.1038/onc.2015.406. Epub 2015 Oct 26.

37.

A PI3K p110β-Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis.

Yuzugullu H, Baitsch L, Von T, Steiner A, Tong H, Ni J, Clayton LK, Bronson R, Roberts TM, Gritsman K, Zhao JJ.

Nat Commun. 2015 Oct 7;6:8501. doi: 10.1038/ncomms9501.

38.

Imaging free-falling particles for multipoint measurement of plasma fluctuations.

Roberts TM, Mauel ME, Abler MC, Makansi BK.

Rev Sci Instrum. 2015 Aug;86(8):083510. doi: 10.1063/1.4929407.

PMID:
26329195
39.

Correction for Hwang et al., Polyomavirus small T antigen interacts with yes-associated protein to regulate cell survival and differentiation.

Hwang JH, Pores Fernando AT, Faure N, Andrabi S, Adelmant G, Hahn WC, Marto JA, Schaffhausen BS, Roberts TM.

J Virol. 2015 Jul;89(13):6971. doi: 10.1128/JVI.00952-15. No abstract available.

40.

Papillomavirus E7 oncoproteins share functions with polyomavirus small T antigens.

White EA, Kramer RE, Hwang JH, Pores Fernando AT, Naetar N, Hahn WC, Roberts TM, Schaffhausen BS, Livingston DM, Howley PM.

J Virol. 2015 Mar;89(5):2857-65. doi: 10.1128/JVI.03282-14. Epub 2014 Dec 24.

41.

The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation.

Csibi A, Lee G, Yoon SO, Tong H, Ilter D, Elia I, Fendt SM, Roberts TM, Blenis J.

Curr Biol. 2014 Oct 6;24(19):2274-80. doi: 10.1016/j.cub.2014.08.007. Epub 2014 Sep 11.

42.

Polyomavirus small T antigen interacts with yes-associated protein to regulate cell survival and differentiation.

Hwang JH, Pores Fernando AT, Faure N, Andrabi S, Adelmant G, Hahn WC, Marto JA, Schaffhausen BS, Roberts TM.

J Virol. 2014 Oct;88(20):12055-64. doi: 10.1128/JVI.01399-14. Epub 2014 Aug 13. Erratum in: J Virol. 2015 Jul;89(13):6971. Adelmant, Guillaume and Marto, Jarrod A [Added].

43.

Polyoma small T antigen triggers cell death via mitotic catastrophe.

Pores Fernando AT, Andrabi S, Cizmecioglu O, Zhu C, Livingston DM, Higgins JM, Schaffhausen BS, Roberts TM.

Oncogene. 2015 May 7;34(19):2483-92. doi: 10.1038/onc.2014.192. Epub 2014 Jul 7.

44.

The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type.

Utermark T, Schmit F, Lee SH, Gao X, Schaffhausen BS, Roberts TM.

J Virol. 2014 Sep;88(18):10673-9. doi: 10.1128/JVI.01409-14. Epub 2014 Jul 2.

45.

KRAS and YAP1 converge to regulate EMT and tumor survival.

Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X, Schinzel AC, Sood S, Rosenbluh J, Kim JW, Zwang Y, Roberts TM, Root DE, Jacks T, Hahn WC.

Cell. 2014 Jul 3;158(1):171-84. doi: 10.1016/j.cell.2014.06.004. Epub 2014 Jun 19.

46.

PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.

Schmit F, Utermark T, Zhang S, Wang Q, Von T, Roberts TM, Zhao JJ.

Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):6395-400. doi: 10.1073/pnas.1323004111. Epub 2014 Apr 15.

47.

Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α.

Gritsman K, Yuzugullu H, Von T, Yan H, Clayton L, Fritsch C, Maira SM, Hollingworth G, Choi C, Khandan T, Paktinat M, Okabe RO, Roberts TM, Zhao JJ.

J Clin Invest. 2014 Apr;124(4):1794-809. doi: 10.1172/JCI69927. Epub 2014 Feb 24.

48.

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).

Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, Yuan J, Kovats SG, Kim S, Cooke VG, Monahan JE, Stegmeier F, Roberts TM, Sellers WR, Zhou W, Zhu P.

Cancer Discov. 2013 Sep;3(9):1030-43. doi: 10.1158/2159-8290.CD-13-0142. Epub 2013 Jul 10.

49.

Spatial trends and factors affecting mercury bioaccumulation in freshwater fishes of Washington State, USA.

Mathieu C, Furl CV, Roberts TM, Friese M.

Arch Environ Contam Toxicol. 2013 Jul;65(1):122-31. doi: 10.1007/s00244-013-9882-8. Epub 2013 Feb 23. Erratum in: Arch Environ Contam Toxicol. 2013 Jul;65(1):171. Mattieu, Callie A [corrected to Mathieu, Callie].

PMID:
23435684
50.

Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention.

Jia S, Gao X, Lee SH, Maira SM, Wu X, Stack EC, Signoretti S, Loda M, Zhao JJ, Roberts TM.

Cancer Discov. 2013 Jan;3(1):44-51. doi: 10.1158/2159-8290.CD-12-0262. Epub 2012 Dec 20.

Supplemental Content

Loading ...
Support Center